PO.PS01.02 · 人群科学

恶性眼睑肿瘤的流行病学、生存及预后因素：一项为期17年的基于人群的研究

Epidemiology, survival, and prognostic factors of malignant eyelid tumors: A 17-year population-based study

编号 3574 展板 24 时间 4/20 02:00–05:00 区域 Section 34 主讲 said yaseen

分会场 Cancer Surveillance: Emerging Cancer Trends and Population Differences

查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

said yaseen¹, Bashar I. Almaraziq², Shaimaa A. Abdelmoneim³, Ahmad S. Al Sakini⁴, Hamza Khoursheed¹, Joud K. Alhousani¹, Alhareth Alhusban⁵, Leen Abu Rabi¹, Ahmad Farouk Alzein⁶, Issam Khourshid⁷, Mohammad Almajali¹, Hashem Abu Serhan⁸

¹Jordan University of Science and Technology, Irbid, Jordan,²School of Medicine,, Hashemite University, Zarqa, Jordan,³Egyptian Ministry of Health and Population, Alexandria, Egypt,⁴University of Baghdad, Baghdad, Iraq,⁵University of Jordan, Amman, Jordan,⁶University of Illinois Chicago, Chicago, IL,⁷Victoria Hospital, Scotland, Kirkcaldy, United Kingdom,⁸Hamad Medical Corporation, Doha, Qatar

摘要 Abstract

中文摘要

目的：本研究旨在描述原发性恶性眼睑肿瘤——特别是皮脂腺癌、恶性黑色素瘤和Merkel细胞癌（MCC）——的流行病学、生存结局及预后因素。方法：我们对来自监测、流行病学和最终结果（SEER）数据库的2004-2021年间诊断的3,082例原发性眼睑恶性肿瘤病例进行了回顾性分析。患者按组织学亚型、年龄、种族、肿瘤分期和治疗方式进行分类。采用Kaplan-Meier生存分析、log-rank检验和Cox比例风险回归来评估生存并识别预后因素。结果：皮脂腺癌是最常见的亚型（26.57%），其次为恶性黑色素瘤和MCC。大多数患者（77.28%）年龄超过60岁。虽然白人个体占多数（86.9%），但皮脂腺癌在亚裔或太平洋岛民人群中的患病率较高（11.8%）。MCC在诊断时的远处转移率最高（19.4%）。手术是主要治疗方式（81.6%）。生存结局因组织学类型不同而存在显著差异：MCC预后最差（5年生存率：43.1%；中位数：48个月），而黑色素瘤最佳（5年生存率：71.7%；中位数：164个月）。Cox回归确定年龄>60岁（HR：4.25）和放射治疗（HR：2.01）为不良生存的显著预测因素。结论：恶性眼睑肿瘤在生存方面表现出显著的异质性。MCC与最高的死亡率相关，高龄和放射治疗是关键的预后因素，这凸显了针对组织学类型制定管理策略的必要性。

查看英文原文 English abstract

Purpose: This study aimed to characterize the epidemiology, survival outcomes, and prognostic factors of primary malignant eyelid tumors, specifically sebaceous adenocarcinoma, malignant melanoma, and Merkel cell carcinoma (MCC). Methods: We conducted a retrospective analysis of 3,082 cases of primary eyelid malignancies diagnosed between 2004-2021 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were categorized by histological subtype, age, race, tumor stage, and treatment modality. Kaplan-Meier survival analysis, log-rank tests, and Cox proportional hazards regression were employed to evaluate survival and identify prognostic factors. Results: Sebaceous adenocarcinoma was the most prevalent subtype (26.57%), followed by malignant melanoma and MCC. Most patients (77.28%) were over 60 years old. While White individuals constituted the majority (86.9%), sebaceous adenocarcinoma showed a higher prevalence in Asian or Pacific Islander populations (11.8%). MCC exhibited the highest rate of distant metastases at diagnosis (19.4%). Surgery was the primary treatment (81.6%). Survival outcomes varied significantly by histology: MCC had the worst prognosis (5-year survival: 43.1%; median: 48 months), whereas melanoma had the best (5-year survival: 71.7%; median: 164 months). Cox regression identified age >60 years (HR: 4.25) and radiation therapy (HR: 2.01) as significant predictors of poor survival. Conclusion: Malignant eyelid tumors exhibit significant heterogeneity in survival. MCC is associated with the highest mortality, and advanced age and radiation therapy are key prognostic factors, underscoring the need for histology-specific management strategies.

利益披露 Disclosure

S. yaseen, None.. B. I. Almaraziq, None.. S. A. Abdelmoneim, None.. A. S. Al Sakini, None.. H. Khoursheed, None.. J. K. Alhousani, None.. A. Alhusban, None.. L. Abu Rabi, None.. A. F. Alzein, None.. I. Khourshid, None.. M. Almajali, None.. H. Abu Serhan, None.

← 返回 AACR 2026 检索